{"id":"NCT04377711","sponsor":"Covis Pharma S.Ã .r.l.","briefTitle":"A Study of the Safety and Efficacy of Ciclesonide in the Treatment of Non-hospitalized COVID-19 Patients","officialTitle":"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Ciclesonide Metered-Dose Inhaler in Non-hospitalized Patients 12 Years of Age and Older With Symptomatic COVID-19 Infection","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-06-08","primaryCompletion":"2021-01-05","completion":"2021-01-05","firstPosted":"2020-05-06","resultsPosted":"2022-01-06","lastUpdate":"2023-02-09"},"enrollment":400,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["COVID-19"],"interventions":[{"type":"DRUG","name":"Ciclesonide","otherNames":["Alvesco"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Group 1","type":"ACTIVE_COMPARATOR"},{"label":"Group 2","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to assess the safety and efficacy of Alvesco (ciclesonide) Inhalation Aerosol in non hospitalized patients with symptomatic COVID-19 infection in a multicenter, randomized, double-blind, placebo controlled study","primaryOutcome":{"measure":"Time to Alleviation of COVID-19-related Symptoms by Day 30","timeFrame":"Day 30","effectByArm":[{"arm":"Ciclesonide Arm","deltaMin":19,"sd":null},{"arm":"Placebo Arm","deltaMin":19,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["34807241","33388170","32738928"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":197},"commonTop":["Dyspnea","Headache","Dry Mouth","COVID-19 (ie, worsening of COVID-19","COVID-19 pneumonia"]}}